<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="155014"><TitleDisplay>Tissue Removal Assessment With Ultrasound of the SFA and Popliteal</TitleDisplay><TitleOfficial>Tissue Removal Assessment With Ultrasound of Tthe SFA and Popliteal</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01938391</Identifier><Identifier type="Organisational Study">TRUTH</Identifier><Identifier type="Trial Acronym">TRUTH</Identifier></Identifiers><Indications><Indication id="260">Peripheral vascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="146" role="Therapeutic effect marker" type="Physiological">Ankle-brachial index</BiomarkerName><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Stealth 360deg OAS</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29620" type="Company"><TargetEntity id="4295899205" type="organizationId">Cardiovascular Systems Inc</TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"></TargetEntity><TargetEntity id="D016491" type="MeSH"></TargetEntity><TargetEntity id="-817414410" type="omicsDisease"></TargetEntity><TargetEntity id="260" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29620">Cardiovascular Systems Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>25</PatientCountEnrollment><DateStart>2013-01-31T00:00:00Z</DateStart><DateEnd type="actual">2015-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:30:57Z</DateChangeLast><DateAdded>2013-09-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>NYU School of Medicine; New York; New York; 10016; United States</Affiliation><Name>AnvarÂ Babaev</Name><Phone>212-263-5656</Phone></Contact><Contact type="Scientific contact"><Affiliation>NYU Langone Medical Center</Affiliation><Name>Anvar Babaev, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject's age &gt;/=  18 years&lt;/li&gt;&lt;li&gt;Subject is an acceptable candidate for percutaneous intervention using the Sponsor's OAS in accordance with its labeled indications and instructions for use&lt;/li&gt;&lt;li&gt;Target lesion(s) located in a superficial femoral artery (SFA), popliteal (POP) or tibioperoneal trunk (TPT)&lt;/li&gt;&lt;li&gt;Tight lesions (&amp;gt; 70% stenosis)&lt;/li&gt;&lt;li&gt;Lesions&amp;lt; 110 mm in length&lt;/li&gt;&lt;li&gt;Artery with the vessel&amp;lt;  6.5 mm in diameter&lt;/li&gt;&lt;li&gt;Subject is willing and able to sign an approved informed consent form&lt;/li&gt;&lt;li&gt;Subject is willing and able to attend follow-up visits&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Uncontrolled allergy to nitinol, stainless-steel or other stent materials or to contrast agent&lt;/li&gt;&lt;li&gt;Unable to take appropriate antiplatelet therapy&lt;/li&gt;&lt;li&gt;Subject has no distal run-off&lt;/li&gt;&lt;li&gt;Interventional treatment is intended for in-stent restenosis at the peripheral vascular site&lt;/li&gt;&lt;li&gt;Subject has history of coagulopathy or hypercoagulable disorder, is undergoing hemodialysis or has impaired renal function (Creatinine [Cr]&amp;gt; 2.5 mg/dl) at the time of treatment&lt;/li&gt;&lt;li&gt;Female subject who is pregnant or nursing a child&lt;/li&gt;&lt;li&gt;Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Sponsor's OAS&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Rate of Clinically Driven Target Lesion Revascularization (TLR): a Kaplan-Meier analysis was performed to determine the percent probability that a study participant had a TLR at 6 months and at 12 months</Description><Timeframe>6 and 12 months</Timeframe></Measure><Measure><Description>Mean Maximum Balloon Inflation Pressure: mean maximum balloon inflation pressure of balloons used pre-stent placement</Description><Timeframe>Index Procedure</Timeframe></Measure><Measure><Description>Rate of Procedural Angiographic Complications: percent of study participants with an Investigator reported procedural angiographic complication (flow limiting dissection, perforation, slow flow/no flow, distal embolization and recoil)</Description><Timeframe>Index Procedure</Timeframe></Measure><Measure><Description>Ankle-Brachial Index (ABI) Measurments: the ankle-brachial index (ABI) is the ratio of the systolic blood pressure (SBP) measured at the ankle to that measured at the brachial (upper arm) artery. Normal range of ABI is 0.9 to 1.2. Values &lt;  0.9 suggests presence of peripheral artery disease (PAD). Values greater than 1.2 suggests of non-compressible vessel</Description><Timeframe>Baseline, 2 weeks, 6 and 12 months</Timeframe></Measure><Measure><Description>Rutherford Classification (RC): Rutherford Classification (RC) is a commonly used clinical grading system for describing peripheral arterial disease (PAD) on a scale of 0 to 6. RC 6 is the most severe form of PAD. The RC is assessed for each participant at baseline and at each follow-up visit. RC classification is as follows: RC 0: Asymptomatic, no hemodynamically significant occlusive disease RC 1-3: Mild to Severe Claudication, limitation with ordinary physical activities, patient is comfortable at rest RC 4-5: Ischemic rest pain, minor tissue loss, non healing ulcer, focal gangrene RC 6: Major tissue loss, functional foot no longer salvageable</Description><Timeframe>Baseline, 2 weeks, 6 and 12 month</Timeframe></Measure><Measure><Description>Stent Usage at the Time of the Index Procedure: number of lesions with a stent placed during the index procedure</Description><Timeframe>Index Procedure</Timeframe></Measure><Measure><Description>Percent (%) Area Stenosis: Percentage (%) of area stenosis as assessed by the intravascular ultrasound (IVUS) Core Lab. Percentage of area stenosis was calculated as 1 - (minimum lumen area / reference lumen area)</Description><Timeframe>Index Procedure (pre-procedure, post-OAS treatment and post-balloon treatment)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this prospective, single-arm (non-randomized), post-market study   in which Intravascular Ultrasound (IVUS) imaging   body  will be utilized to assess performance of the Sponsor's Orbital Atherectomy      System (OAS) followed by adjunctive balloon angioplasty (BA) in patients who have      symptomatic peripheral artery disease (PAD) occurring in the Superficial Femoral Artery      (SFA), Popliteal (POP),and/or Tibioperoneal Trunk (TPT).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be treated with Stealth 360deg OAS. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>NYU School of Medicine</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10157">Subjects with History of PAD Interventions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01938391</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21813"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21816">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19226"><Criterion>Subjects with Inclusion Based On Location/Anatomy of Vessel</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19228">Subjects with femoropopliteal disease</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="19230">Subjects with superficial femoral artery (SFA) disease</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="19232">Stenosis/Occlusion of the artery/lesion</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="19233">Target lesion length and size as per the protocol</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="19234">Target vessel diameter as per the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19287"><Criterion>Subjects with PAD Interventions</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15960"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15966">Subjects co-morbid with coagulation disorder/dysfunction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15980"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16033"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16045"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16054"><Criterion>Subjects with Inappropriate Vascular/Vessel Anatomy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16055">Subjects with in-stent restenosis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-02-28T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-03-12T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>